{"groups":[{"description":"Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus best supportive care (BSC) until disease progression, withdrawal of consent, death, or intolerance of study drug.","id":"FG000","title":"Panitumumab + BSC"},{"description":"Participants received best supportive care until disease progression, withdrawal of consent, or death.","id":"FG001","title":"BSC Alone"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"22"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"136"},{"groupId":"FG001","numSubjects":"133"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"189"},{"groupId":"FG001","numSubjects":"188"}],"type":"STARTED"},{"achievements":[{"comment":"Participants continuing study at the time of data cut-off","groupId":"FG000","numSubjects":"40"},{"comment":"Participants continuing study at the time of data cut-off","groupId":"FG001","numSubjects":"31"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"149"},{"groupId":"FG001","numSubjects":"157"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were stratified according to geographic region (Europe vs Asia vs rest of the world) and Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1 vs 2) and randomized (1:1 ratio) to 1 of 2 treatment groups.","recruitmentDetails":"A total of 377 participants were randomized at 66 centers in Europe, Asia, North and South America from 8 November 2011 until 30 July 2013.\n\nResults are reported as of the primary analysis data cut-off date of 10 June 2014."}